japan-header

JAPAN

Aspen’s subsidiary in Japan was officially opened in May 2015. Aspen Japan operates according to a flexible business model and employs innovative marketing activities to promote leading international pharmaceutical originator brands and authorised generics in Japan.

Contribution to Group revenue

japan-contrib

Revenue contribution - by therapeutic category

japan
  • The Japanese pharmaceutical sector declined 4,5% and was valued at USD80 billion as at 30 June 2017.
  • The sector was negatively impacted by a 20,6% decline in off-patent drugs due to price revisions and increased generic penetration.

Source: June 2017 IMS

STATISTICS

Number of products launched:

5

(2016: 7)

IMS value of pipeline as at 30 June 2017 anticipated to be launched in:

0 – 2 years

USD nil

3 – 5 years

USD1 million

Number of product recalls:

Nil

(2016: nil)

Average staff turnover:

20,0%

(2016: 20,7%)

Number of work-related fatalities:

Nil

(2016: nil)

Number of permanent employees:

japan-employees

Revenue – R’billion20172016 (CER)*% change
Total1,90,6>100
Anaesthetics1,3>100
High Potency & Cytotoxics0,40,5(16)
Other Commercial Pharmaceutical Brands0,20,167

* Constant exchange rate: FY16 restated at FY17 average exchange rates.
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.